France’s Bold Frontier: How the Early Access Programme (AAP) is Redefining Hope, Access, and Reimbursement in 2025. It is one of the most sophisticated early access and temporary reimbursement frameworks in global healthcare, enabling publicly funded patients to access breakthrough therapies even before they obtain full marketing authorisation or a formal listing on LPPR (Liste des Produits et Prestations Remboursables). Inside France’s fearless AAP and ATU early access reimbursement revolution—where innovation meets evidence and patients receive tomorrow’s cures today.
For biopharmaceutical companies, especially those working in cancer treatment, gene therapy, and rare diseases, this system is not just about getting patients access early; it also serves as a key step towards securing long-term reimbursement through the HAS, CEPS, and CNAM.
France’s AAP and ATU early access reimbursement frameworks represent one of the world’s most ambitious commitments to patient-centred innovation. By enabling temporary reimbursement before full market authorisation, they empower hospitals, researchers, and patients to access life-saving genes and cell therapies years earlier. This is more than policy—it’s France turning data into compassion and evidence into access. Inside France’s fearless AAP and ATU early access reimbursement revolution—where innovation meets evidence and patients receive tomorrow’s cures today.
The 2021 Revolution That Rewired French Market Access and Patient Hope
Until 2021, early access to medicines in France operated under the ATU (Autorisation Temporaire d’Utilisation) scheme a mechanism that quietly allowed patients to receive breakthrough therapies ahead of full marketing approval. This old system was completely changed by the Social Security Financing Law (LFSS 2021), creating a new approach based on evidence that strengthens France’s reputation for innovative healthcare access.
The reform introduced two complementary mechanisms within France’s AAP and ATU early access reimbursement framework, designed to align real-world evidence with rapid patient benefit:
- AAP (Accès Précoce)—France’s flagship early access route for therapies demonstrating high clinical potential and unmet needs. Medicines may be used before EU Marketing Authorisation (MA) or for unapproved indications. They receive 100% public reimbursement via the CNAM (Caisse Nationale d’Assurance Maladie), under a temporary price ceiling defined by the CEPS (Comité Économique des Produits de Santé), and are rigorously evaluated by HAS (Haute Autorité de Santé) for both clinical and medico-economic benefit.
(Keywords: AAP France, early access reimbursement, HAS evaluation, CNAM CEPS pricing, LFSS 2021) - AAPC (Accès Compassionnel)—a compassionate access pathway reserved for non-commercial treatments, often used in palliative, rare, or last-line disease settings. This program ensures that even when no formal market authorisation is planned, patients still have a publicly funded route to healthcare.
(Keywords: compassionate use, France, AAPC, ANSM, rare disease reimbursement)
This quiet revolution in French reimbursement policy has rewired how evidence, compassion, and economics intersect. While many policy shifts across Europe have adjusted access rules, France’s LFSS 2021 reform stands apart—boldly reframing access as an evidence-for-equity contract between innovation and the state.
A Coordinated, Evidence-Based Framework for Reimbursement
France’s AAP and ATU early access reimbursement ecosystem operates through a finely tuned collaboration among four national authorities, each essential to turning scientific discovery into funded patient care. Together, they form a uniquely evidence-based policy engine—a model now studied across Europe for its precision and transparency.
- The Haute Autorité de Santé (HAS) serves as the system’s scientific and economic foundation. HAS assesses the Service Médical Rendu (SMR) and Amélioration du Service Médical Rendu (ASMR) to determine early access eligibility. It also defines real-world evidence (RWE) obligations that will later inform CEPS pricing negotiations and permanent inclusion on the LPPR (Liste des Produits et Prestations Remboursables).
(Keywords: HAS France, SMR ASMR, RWE France, AAP early access evaluation) - The ANSM (Agence nationale de sécurité du médicament et des produits de santé) serves as France’s guardian of pharmacovigilance and safety. ANSM supervises data integrity, compassionate use requests under the AAPC, and risk management plans for all therapies under temporary authorisation.
(Keywords: ANSM France, pharmacovigilance, compassionate use, AAPC) - CNAM (Caisse Nationale d’Assurance Maladie)—the country’s central payer authority that establishes temporary reimbursement agreements and guarantees hospital funding during early access phases. Through CNAM, all approved AAP and ATU products receive 100% national insurance reimbursement, reflecting France’s strong public-funding commitment to innovation.
(Keywords: CNAM reimbursement France, temporary reimbursement, hospital funding ) - CEPS (Comité Économique des Produits de Santé)—the economic negotiator responsible for transforming early-access data into final market value. CEPS sets temporary price limits for AAP, and after real-world evidence and HAS evaluations are finished, it negotiates the final price that will allow the product to be permanently included on the LP
(Keywords: CEPS France, LPPR pricing, post-RWE negotiation)
Behind every reimbursed molecule lies an orchestra of agencies—each playing its note in perfect synchrony. This choreography of reimbursement transforms France’s health system into a living evidence laboratory, where policy, science, and compassion move in rhythm to bring tomorrow’s therapies to patients today
How AAP Products Are Funded
Once a therapy is accepted under France’s AAP and ATU early access reimbursement framework, it moves from scientific promise to fully funded patient reality. Every approved product receives 100 % reimbursement through the French national insurance system (CNAM), reflecting the government’s commitment to publicly financed innovation and rapid patient access.
Under the AAP, the price is based on a temporary maximum reimbursement amount, which limits how much can be spent while more evidence is being gathered. These ceilings are published twice a year in the Journal Officiel, ensuring transparency and equity across hospitals and manufacturers.
(Keywords: temporary reimbursement France, CNAM early access funding, montants de remboursement maximaux, Journal Officiel)
Every euro spent on the AAP program carries a scientific obligation. Manufacturers must provide ongoing real-world evidence (RWE) via patient registries, hospital reporting, and outcome monitoring, which directly informs HAS re-evaluation and subsequent CEPS price negotiations. This mechanism transforms temporary reimbursement into a data-driven investment, where evidence—not assumptions—defines value.
(Keywords: RWE France, HAS CEPS evaluation, early access reimbursement data, real-world evidence collection)
In this way, France’s AAP and ATU system stands apart from traditional access schemes: it doesn’t just fund innovation early—it funds it intelligently, turning each reimbursed treatment into a living economic experiment that shapes the country’s next generation of value-based healthcare policy.
2025 Snapshot: A Rapidly Expanding Ecosystem
As of April 2025, 366 therapies covering 236 unique INNs (active substances) have benefited from early reimbursement under AAP, a 10% increase since September 2024. The portfolio spans:
- Gene and cell therapies (CAR-T, AAV-based vectors);
- Next-generation immuno-oncology agents (PD-1, CTLA-4, bispecific antibodies);
- Orphan drugs for ultra-rare diseases such as spinal muscular atrophy and metabolic disorders.
This scale demonstrates France’s commitment to innovation-led reimbursement, positioning it as Europe’s most proactive environment for conditional funding and evidence generation.
Notable new entries include:
As of early 2025, France’s Early Access Programme (AAP) continues to attract some of the world’s most advanced therapies across oncology, rare diseases, and genetic medicine. Below are several key new entrants that underscore the system’s breadth and scientific ambition.
| Product (Brand) | INN / Molecule | Indication (Simplified) | Scientific/clinical context |
|---|---|---|---|
| Vyjuvek | beremagene geperpavec | Dystrophic epidermolysis bullosa (DEB) | This is the first time a topical gene therapy for a rare paediatric skin fragility disorder has received approval. Vyjuvek delivers a functional COL7A1 gene via a modified HSV-1 vector, restoring collagen VII production. Its inclusion under AAP highlights France’s support for genetic medicines with ultra-rare indications and unmet clinical needs. (Keywords: gene therapy France, rare disease reimbursement, AAP HAS CNAM) |
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | A bispecific BCMA-CD3 T-cell engager showing a durable response in heavily pretreated myeloma patients. France’s early funding recognises its potential to transform refractory haematologic oncology care, complementing CAR-T therapies under AAP. (Keywords: bispecific antibody, France, oncology reimbursement, early access program) |
| Livmarli | maralixibat | Progressive familial intrahepatic cholestasis (PFIC) | It is a selective ileal bile acid transporter (IBAT) inhibitor that alleviates pruritus and enhances bile flow. Livmarli’s inclusion under AAP reflects HAS’s prioritisation of paediatric orphan drugs and quality-of-life endpoints for rare hepatic diseases. (Keywords: IBAT inhibitor, rare liver disease France, AAP reimbursement) |
| Jakavi | ruxolitinib | Graft-versus-host disease (GVHD) | A JAK1/2 inhibitor long used in myelofibrosis, now extended to steroid-refractory GVHD. Its early access approval illustrates France’s willingness to fund repurposed molecules in high-mortality immune complications pending label expansion. (Keywords: Jakavi GVHD France, ruxolitinib reimbursement, HAS early access) |
| Elahere | mirvetuximab soravtansine | Ovarian and fallopian tube cancers | A first-in-class antibody-drug conjugate (ADC) targeting folate receptor-α (FRα). AAP access supports urgent unmet needs in platinum-resistant ovarian cancer, pending broader EU authorisation. (Keywords: ADC France reimbursement, oncology early access, ovarian cancer AAP) |
| Winrevair | sotatercept | Pulmonary arterial hypertension (PAH) | A first-in-class activin signalling inhibitor (TGF-β superfamily) that improves pulmonary vascular resistance and exercise capacity. Early access in France underscores its breakthrough designation and the health system’s commitment to cardiopulmonary innovation. (Keywords: sotatercept France, PAH therapy reimbursement, CEPS pricing) |
| Vylov | zolbetuximab | HER2-negative advanced gastric cancer | A CLDN18.2-targeting monoclonal antibody showing significant survival benefit in metastatic gastric cancer. France’s inclusion under AAP supports precision oncology beyond HER2-positive populations and facilitates real-world data collection for CEPS pricing negotiation. (Keywords: zolbetuximab France, gastric cancer, HAS oncology reimbursement) |
Why These AAP Inclusions Matter
Each of these therapies represents a strategic reimbursement pilot within France’s innovation-driven health system. Their acceptance reflects HAS’s increasing openness to:
- Molecularly targeted and gene-based interventions;
- Paediatric and ultra-rare indications;
- Robust post-marketing evidence commitments (RWE) linked to CEPS pricing reviews.
Together, these approvals demonstrate France’s role as Europe’s early adopter of high-cost, high-impact therapeutics, where clinical promise precedes commercial certainty, a model now being closely observed by EU-HTA and EMA collaborative pathways.
These additions underscore the scientific and economic openness of the French system toward:
- First-in-class mechanisms
- Ultra-orphan populations
- Real-world validated endpoints
- Drugs priced in the millions, such as PTC Therapeutics’ Upstaza (€3.5 million)
Unlike some EU systems where early access is limited to nominal pricing or unfunded “named patient use,” France enables full public reimbursement with transparent upper-limit pricing, often in line with expected future list prices.
Key principles include:
- Temporary, capped price (montant maximal de remboursement) does not lock in CEPS pricing.
- Companies are obliged to submit a final dossier for CEPS price negotiation and Transparency Committee (CT) assessment after early access ends.
- Volume and budget impact are reviewed retrospectively, and overcompensation may lead to paybacks (remboursements à posteriori) to CNAM.
According to the French Cour des Comptes (Court of Audit), in 2023 alone, over €1.4 billion was spent through early access mechanisms but offset by reduced hospitalisations and emergency interventions, especially in oncology and CAR-T applications. (Ref: Cour des Comptes, Rapport sur les comptes de la sécurité sociale 2024).
Entry into AAP is not merely a shortcut to market. It demands a scientific and real-world commitment:
- Post-entry, manufacturers must submit data on safety, usage, early efficacy signals and economic value.
- HAS uses this data to assess service médical rendu (SMR) and amélioration du service médical rendu (ASMR) – key criteria for permanent reimbursement.
- Hospitals and prescribers are obliged to report treatment outcomes, contributing to a national RWE evidence base.
This aligns with France’s 2023–2027 National Health Data Strategy, which emphasises using health data (via SNDS and EDS) to power both HTA and real-time clinical improvement.
While other EU countries such as Germany (via NUB), Italy (Law 648/96) and the UK (NHS EAMS) have early access frameworks, France’s AAP is currently the most transparent, high-value and structurally integrated into HTA and payer planning.
For biotechs with gene therapies, ultra-rare indications or post-Phase II oncology products, this creates:
- A risk-sharing pre-launch model
- A pricing data point for other EU negotiations
- A de-risking tool for investors
France’s Early Access Program is no longer a niche or exceptional route. It has become a core element of the French reimbursement ecosystem, particularly for advanced biologics and cell/gene therapies. With 366 products covered as of April 2025 and millions allocated to rare and complex treatments, the message is clear: if you have an innovative, high-impact therapy, France offers a real-world, reimbursed, and scientifically aligned route to patients and payers.
How to Apply for France’s Early Access Programme (AAP): Step-by-Step Process, Timelines, and Key Stakeholders
France AAP Submission Process: HAS, ANSM, and CNAM Explained
Learn how France’s AAP early access program works, including submission steps, timelines, evidence requirements, and stakeholder roles for temporary reimbursement. France’s Article 51 framework, created by the 2018 Social Security Financing Law (LFSS 2018), officially allows for trying out new methods in national health policy by making exceptions to the usual funding rules. Article 51 creates a three-step review process to see if the project is feasible, examine initial results, and evaluate the overall effect so that the Ministry of Health, CNAM, and HAS can decide on new projects. This adaptive framework, funded through the FISS (Fonds d’Innovation du Système de Santé), has since evolved into the cornerstone of France’s health-system transformation, supporting over 100 projects with €460 million in authorised spending by 2021 (Ministère de la Santé 2021; IRDES 2022). It demonstrates how evaluation-driven experimentation—combining local leadership via ARS with national oversight through HAS and CNAM—has become France’s model for legally financing innovation in healthcare organisations through digitisation and reimbursement.
Overview
France’s Accès Précoce (AAP) system provides temporary reimbursement and early patient access to promising therapies before marketing authorisation or for unapproved indications. Managed jointly by HAS, ANSM, and CNAM, it is designed for medicines showing strong clinical benefit, high unmet need, and likely future MA approval. Behind the Curtain: How France Funds Breakthrough Therapies Under AAP
Step-by-Step AAP Process
1. Sponsor Eligibility and Pre-Submission Preparation
- Who applies: Only the Marketing Authorisation Holder (MAH) or sponsor company can submit an AAP application — usually represented in France by an affiliate or regulatory agent.
- Preliminary alignment: Sponsors should consult HAS and ANSM informally before submission to confirm eligibility (e.g., clinical maturity, unmet need, comparator readiness).
- Key dossier elements:
- Clinical efficacy and safety data (Phase II/III or strong interim results);
- Target population and unmet need analysis;
- Anticipated marketing authorisation timeline;
- Risk management plan and pharmacovigilance strategy;
- Real-world data (RWD) / registry collection plan;
- Proposed pricing ceiling (montant de remboursement maximal).
2. Formal Application Submission
- Platform: Applications are submitted via the HAS and ANSM joint online portal, introduced in 2022 to streamline ATU-to-AAP transitions.
- Required documentation:
- Formulaire de demande d’accès précoce (application form);
- Clinical evaluation dossier (HAS template);
- Benefit–risk assessment (ANSM format);
- Pharmacovigilance protocol;
- Economic justification (preliminary cost-effectiveness or budget impact statement).
- Responsible authorities:
- HAS (Haute Autorité de Santé) — assesses expected clinical benefit (Service Médical Rendu, SMR) and improvement (ASMR).
- ANSM (Agence nationale de sécurité du médicament) — validates safety, risk management, and product quality.
3. Joint HAS–ANSM Review and Decision
- Timeline: Approximately 80–100 days from submission to joint decision.
- Coordination:
- ANSM issues a safety opinion;
- HAS’s Commission de la Transparence provides a scientific and medico-economic opinion;
- Both jointly deliver a final recommendation to the Ministry of Health.
- Decision criteria:
- Serious, rare, or disabling disease;
- Absence of suitable therapeutic alternatives;
- Strong presumption of clinical efficacy;
- Commitment to submit for MA (EU or France) within defined timeframe;
- Comprehensive pharmacovigilance plan.
4. CNAM and CEPS Reimbursement Negotiation
Once approved by HAS and ANSM:
- CNAM establishes a temporary reimbursement agreement, setting the price ceiling (montant de remboursement maximal) for the product.
- CEPS (Comité Économique des Produits de Santé) later uses real-world evidence (RWE) data from AAP use to negotiate final post-MA pricing for LPPR or standard reimbursement listing.
- Timeline:
- CNAM price and reimbursement publication: ~1 month post-decision;
- Temporary funding via hospital budgets (MIGAC) begins immediately thereafter.
5. Real-World Evidence (RWE) Obligations
- Sponsors must commit to RWE data collection — typically via:
- National registries (e.g., EPIPHARE collaboration);
- Hospital data collection;
- Post-AAP HAS evaluation dossier.
- These data are mandatory for final CEPS price negotiation and HAS transparency committee reassessment post-marketing authorisation.
Indicative Timelines
| Phase | Authority | Approx. Duration | Outcome |
|---|---|---|---|
| Pre-submission consultation | HAS / ANSM | 2–4 weeks | Eligibility confirmation |
| Application submission | Sponsor | – | Dossier filing |
| Scientific assessment | HAS / ANSM | 80–100 days | Joint AAP recommendation |
| Reimbursement agreement | CNAM / CEPS | ~30 days | Temporary price ceiling set |
| Implementation & RWE | Sponsor + Hospitals | Ongoing (12–24 months) | Data to inform CEPS price |
AAPC (Accès Compassionnel) Parallel Pathway
For therapies not intended for commercialisation, sponsors can request AAPC, handled solely by ANSM with hospital physician input. These are non-commercial compassionate access programmes, often covering paediatric or palliative cases, with public funding limited to drug costs and no commercial pricing negotiation.
Practical Takeaways for Sponsors
- Engage HAS and ANSM early to verify eligibility and expected clinical endpoints.
- Please ensure that the RWE strategy is credible, as HAS now connects early access approval directly to long-term data collection.
- Predefine your economic narrative: CNAM and CEPS prioritise therapies showing measurable population health or budget impact benefits.
- Coordinate hospital logistics and distribution chains pre-approval — delays in delivery may affect continuation under AAP.
Inside the AAP System: Practical Pathways, Expert Committees, and Strategic Leverage
1. The Official Route but Also the Informal Layer
Formally, the AAP process follows strict coordination between HAS (clinical & medico-economic assessment) and ANSM (safety), with CNAM handling reimbursement and CEPS negotiating later pricing.
However, before dossiers reach the Transparency Committee, they are often socialised informally through specialised clinical networks—and this is where the ARCs (Antibiotic Resistance Coordination Centres/Centres Régionaux d’Antibiothérapie) or Reference Centres in other disease areas play a powerful behind-the-scenes role. The Accès Précoce (AAP) programme represents France’s bold commitment to patient-first innovation—a framework that allows life-changing therapies with exceptional clinical promise to reach patients before full EU marketing authorisation. Under this evidence-driven reimbursement pathway, the HAS and CNAM ensure 100% public funding, while CEPS sets a transparent temporary price ceiling pending real-world validation.
2. The ARC and Reference Centre Committees
Each ARC or CNR (Centre National de Référence) has its own scientific advisory committee, typically composed of:
- Clinical KOLs (university hospital leads, infectious disease or oncology heads);
- Pharmacologists or microbiologists from CHU laboratories;
- Representatives from Agence Régionale de Santé (ARS);
- Epidemiologists linked to SPF (Santé Publique France);
- Sometimes observers from HAS or CNAM attend alignment discussions.
These committees do not approve AAPs directly, but they advise on medical need, clinical positioning, and comparator selection—which later influences HAS’s perception of “unmet need” (besoin médical non couvert).
Practical trick: If your therapy or diagnostic aligns with an ARC’s regional AMR or disease-control priority (for example, an innovative UTI diagnostic under the CRAtb network), an early presentation to their committee can pre-emptively strengthen the “public health justification” part of your HAS dossier.
3. Early Engagement and Evidence Pre-Alignment
Successful sponsors usually:
- Engage expert centres. 3–6 months before submission, offering preliminary data or planned trial outcomes;
- Request avis scientifiques préalables (informal scientific advice) from HAS and sometimes ARC-affiliated clinicians;
- Use ARC or CHU endorsement letters in the Justification du besoin médical section — a move that can materially shorten HAS deliberation time.
These endorsements create contextual legitimacy in France’s consensus-based system, showing alignment with national or regional health priorities (e.g., Plan National Antibiorésistance 2022–2025).
4. Integration of Real-World Evidence Networks €1.4 Billion of Boldness: Why France Invests Early in Medical Miracles
Under AAP, post-approval RWE collection is mandatory. France leverages ARC/CRAtb networks and CHU registries to implement this efficiently.
- Many AAP sponsors establish a registry partnership with a regional ARC or reference network to monitor outcomes and safety.
- ARC networks already manage surveillance data pipelines connected to Santé publique France and EPIPHARE, which makes RWE integration seamless and credible.
Tactical advantage: Partnering with an ARC or CRAtb for data collection not only fulfils HAS’s RWE obligations but also positions the sponsor for future CEPS price defence using robust, real-world French data.
5. Informal Consultation Points (“Les Comités de Suivi”)
In addition to HAS and ANSM committees, there are Comités de suivi de l’accès précoce, convened roughly quarterly, bringing together:
- HAS transparency representatives;
- CNAM reimbursement analysts;
- CEPS economic officers;
- Clinical experts from ARCs and CHUs;
- Patient associations (for oncology, neurology, AMR, etc.).
These groups track ongoing AAPs and flag implementation challenges.
Sponsors with favourable ARC relationships can sometimes secure invitations to present early outcomes or clarify access bottlenecks, smoothing the transition to full LPPR inclusion later.
6. Timeline Influence via Expert Consensus
Although HAS and ANSM target ~100 days for review, an early scientific consensus note or ARC-backed justification often shortens real processing to 70–80 days, because:
- The “unmet need” criterion has already been validated by clinical networks;
- CNAM faces less internal challenge on budget justification when regional networks have signalled clinical urgency.
7. Strategic Summary: “The Quiet Levers of AAP Success”
| Leverage Point | Stakeholders Involved | Practical Benefit |
|---|---|---|
| Pre-submission scientific dialogue | HAS, ANSM | Clarifies eligibility & evidence level |
| Early ARC/CRAtb engagement | Regional CHU experts | Validates unmet need; accelerates review |
| Registry collaboration for RWE | ARC, SPF, EPIPHARE | Satisfies data obligations; supports CEPS pricing |
| Participation in comité de suivi | HAS, CNAM, ARS | Improves visibility & alignment |
| CHU clinical champion | Local investigator | Facilitates hospital adoption post-AAP |
Further Reading:
- HAS Early Access Portal
- Cour des Comptes Social Security Expenditure Reports
- French Social Security Code: Articles L5121-12 & R512170: https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000045166651 https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000048703237
Glossary of Terms: Decode France’s Early Access & Reimbursement Language Like an Insider
AAP (Accès Précoce) – Early Access Programme
The Accès Précoce system allows temporary, publicly funded access to innovative medicines before marketing authorisation (MA) or for unapproved indications. It is granted by HAS and ANSM, with reimbursement through CNAM. Introduced under the Social Security Financing Law 2021, AAP replaced the earlier ATU (Autorisation Temporaire d’Utilisation) model.
Keywords: early access France, AAP HAS CNAM, temporary reimbursement France.
AAPC (Accès Compassionnel) – Compassionate Access
A related pathway for non-commercial access to unlicensed medicines intended for serious or rare diseases where no alternatives exist. Managed primarily by ANSM, AAPC applies when a sponsor does not intend to commercialise the product.
Keywords: compassionate use, France, AAPC, ANSM, non-commercial therapy access.
ANSM (Agence nationale de sécurité du médicament et des produits de santé)
France’s National Agency for Medicines and Health Products Safety is responsible for evaluating the quality, safety, and risk–benefit profile of drugs. In the AAP process, ANSM co-signs early access approvals with HAS and oversees pharmacovigilance and RWE data integrity.
Keywords: ANSM France, drug safety authority, pharmacovigilance France.
ASMR (Amélioration du Service Médical Rendu) – Improvement in Medical Benefit
A grading scale (I–V) is used by HAS to measure the incremental therapeutic value of a medicine compared to existing treatments.
- ASMR I–II: Major / important improvement
- ASMR III: Moderate improvement
- ASMR IV–V: Minor or no improvement
ASMR influences pricing negotiations with CEPS and future reimbursement levels.
Keywords: ASMR France, HAS evaluation, CEPS pricing.
ATU (Autorisation Temporaire d’Utilisation)
The former French Temporary Authorisation for Use system (1994–2021), replaced by AAP/AAPC. It allowed pre-marketing use of unlicensed medicines on compassionate or nominative grounds.
Keywords: ATU France, temporary authorisation, early access history.
CEPS (Comité Économique des Produits de Santé)
The Economic Committee for Health Products is a joint body under the Ministries of Health and Finance that negotiates prices and reimbursement ceilings for medicines and devices. CEPS determines the final post-AAP or post-MA price, based on RWE data, ASMR level, and budget impact.
Keywords: CEPS pricing France, health product negotiation, LPPR listing.
CNAM (Caisse Nationale de l’Assurance Maladie)
The National Health Insurance Fund is responsible for reimbursing AAP medicines and publishing the maximum reimbursement amount (montant de remboursement maximal). CNAM coordinates with CEPS and HAS to manage hospital funding for AAP treatments.
Keywords: CNAM reimbursement, French national insurance, early access funding.
Commercialisation
The formal marketing and sale of a medicine once authorised by the EMA or ANSM. Under AAP, commercialisation occurs later — reimbursement is temporary and contingent on ongoing RWE collection.
Keywords: marketing authorisation France, post-AAP pricing.
EMA (European Medicines Agency)
The European regulatory body responsible for centralised marketing authorisation across the EU. EMA approval is a key condition for transitioning from AAP to full market access.
Keywords: EMA approval, EU marketing authorisation, early access Europe.
HAS (Haute Autorité de Santé)
France’s High Authority for Health, the main scientific and medico-economic body evaluating the clinical benefit (SMR) and improvement in benefit (ASMR) of medicines. In AAP, HAS leads the clinical and economic review and defines RWE obligations for sponsors.
Keywords: HAS France, SMR ASMR evaluation, reimbursement authority.
Hospital Funding (MIGAC)
Short for Missions d’intérêt général et d’aide à la contractualisation, MIGAC funding covers specific missions of public hospitals, including AAP medicine costs. CNAM channels reimbursement through hospital budgets under MIGAC.
Keywords: MIGAC funding France, hospital reimbursement, CNAM AAP payments.
INN (International Non-Proprietary Name)
The generic or scientific name of a pharmaceutical substance (e.g., elranatamab for Elrexfio). Used in HAS and CNAM listings to distinguish unique active substances under AAP.
Keywords: INN France, HAS listings, AAP substances.
LPPR (Liste des Produits et Prestations Remboursables)
The National List of Reimbursable Products and Services for France’s health insurance system. Products initially reimbursed under AAP later transition to LPPR inclusion after HAS final evaluation and CEPS price agreement.
Keywords: LPPR France, reimbursement list, CEPS HAS pathway.
MA (Autorisation de Mise sur le Marché / Marketing Authorisation)
Regulatory approval allowing a drug to be sold commercially. Under AAP, products typically have submitted or pending MA applications and must commit to seeking full authorisation within defined timelines.
Keywords: MA France, EMA approval, market authorisation France.
Montant de Remboursement Maximal (MRM) – Maximum Reimbursement Amount
The temporary ceiling price is set by CNAM and CEPS for each AAP medicine. It ensures public budget control until final CEPS negotiations post-RWE review.
Keywords: MRM France, CNAM price ceiling, temporary reimbursement rate.
RWE (Real-World Evidence)
Data collected outside of clinical trials—from registries, electronic health records, and hospital data — to evaluate real-life effectiveness, safety, and budget impact. Under AAP, sponsors must collect and submit RWE to HAS and CEPS to justify permanent reimbursement.
Keywords: RWE France, real-world data collection, HAS CEPS evidence.
SMR (Service Médical Rendu) – Medical Benefit
An HAS rating system assesses the absolute clinical benefit of a therapy based on disease severity, efficacy, side effects, and public health value.
- Major/Important SMR → Eligible for reimbursement;
- Insufficient SMR → Denied reimbursement.
SMR directly determines reimbursement status; ASMR influences the price.
Keywords: SMR France, HAS clinical benefit, reimbursement criteria.
Social Security Financing Law (LFSS 2021)
The legislative reform that replaced the ATU system with AAP and AAPC. LFSS 2021 codified France’s commitment to early access with structured RWE obligations and transparent reimbursement ceilings.
Keywords: LFSS 2021 France, ATU reform, AAP law.
Transparency Committee (Commission de la Transparence)
A specialised committee within HAS is responsible for issuing SMR/ASMR opinions that guide CEPS pricing and CNAM reimbursement decisions. It also reviews post-RWE reassessments.
Keywords: HAS Transparency Committee, SMR ASMR opinions, reimbursement France.
Unmet Medical Need
A key eligibility criterion for AAP approval. Refers to serious or life-threatening conditions lacking adequate therapeutic alternatives, where early access may significantly improve outcomes.
Keywords: unmet need, France, AAP eligibility, HAS prioritisation.
Workflow Timeline (AAP Standard Process)
Refers to the integrated 80–100 day evaluation window involving HAS and ANSM, followed by 30 days for CNAM reimbursement. Sponsors must then maintain RWE collection for 12–24 months before CEPS final price negotiation.
Keywords: AAP process timeline, CNAM reimbursement period, HAS ANSM coordination.
Reference List
- Cour des Comptes (2024). Rapport sur les comptes de la sécurité sociale 2024 – Les dépenses liées aux dispositifs d’accès précoce et compassionnel. Paris: Cour des Comptes.
- Ministère des Solidarités et de la Santé (2021). Loi de financement de la sécurité sociale pour 2021 (LFSS 2021). Paris: Journal Officiel de la République Française.
- Haute Autorité de Santé (HAS) (2024). Accès précoce aux médicaments – Modalités d’évaluation et obligations de preuve RWE. Available at: https://www.has-sante.fr
- Agence Nationale de Sécurité du Médicament (ANSM) (2025). Rapport d’activité 2024 – Dispositifs AAP et AAPC. Available at: https://ansm.sante.fr
- Caisse Nationale d’Assurance Maladie (CNAM) (2025). Données de remboursement des médicaments en accès précoce. Available at: https://www.ameli.fr
- Comité Économique des Produits de Santé (CEPS) (2024). Rapport d’activité 2023 – Encadrement des prix temporaires et négociations post-AAP. Paris: Ministère de la Santé et des Finances.
- EPIPHARE (HAS–ANSM Groupement d’intérêt scientifique) (2024). Suivi des médicaments en accès précoce et collecte des données du monde réel.
- IRDES (Institut de Recherche et Documentation en Économie de la Santé) (2022). Les dispositifs de l’article 51 et l’innovation dans le système de santé français. Paris: IRDES.
- Santé Publique France (2023). Données sur les essais cliniques et l’accès précoce aux thérapies innovantes.
- European Medicines Agency (EMA) (2025). Conditional marketing authorisations and early access programmes – EMA Annual Report 2024.
- Legifrance (2025). Articles L5121-12 et R5121-70 du Code de la santé publique – Accès précoce et compassionnel. Available at: https://www.legifrance.gouv.fr
- Ministère de la Santé et de la Prévention (2023). Stratégie nationale des données de santé 2023–2027.